Roberto Chalela

ORCID: 0000-0003-4835-3852
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lung Cancer Treatments and Mutations
  • Lung Cancer Diagnosis and Treatment
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Cancer Immunotherapy and Biomarkers
  • Asthma and respiratory diseases
  • COVID-19 Clinical Research Studies
  • COVID-19 and healthcare impacts
  • Diagnosis and treatment of tuberculosis
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Pulmonary Hypertension Research and Treatments
  • RNA modifications and cancer
  • Inhalation and Respiratory Drug Delivery
  • Venous Thromboembolism Diagnosis and Management
  • Gas Sensing Nanomaterials and Sensors
  • Infectious Diseases and Tuberculosis
  • Lung Cancer Research Studies
  • Advanced Chemical Sensor Technologies
  • Tuberculosis Research and Epidemiology
  • Cancer Genomics and Diagnostics
  • Pediatric health and respiratory diseases
  • Medical Imaging and Pathology Studies
  • Shoulder Injury and Treatment
  • Respiratory Support and Mechanisms
  • Long-Term Effects of COVID-19
  • Ion Transport and Channel Regulation

Hospital Del Mar
2016-2025

Universitat Pompeu Fabra
2016-2024

Hospital del Mar Research Institute
2016-2024

Municipal Institute for Medical Research
2016-2024

Instituto de Salud Carlos III
2016-2021

Centro de Investigación Biomédica en Red de Enfermedades Respiratorias
2014-2021

Parc de Salut
2016-2018

John Wiley & Sons (United States)
2018

Barcelona Biomedical Research Park
2018

Virginia Commonwealth University
2018

Chronic thromboembolic pulmonary disease (CTEPD) consists of persistent vascular obstruction on imaging and involves long-term functional limitations, with or without chronic hypertension (CTEPH). The aim this study was to evaluate the incidence risk factors both defects CTEPH after hospitalization in patients COVID-19 PE during a 2-year follow-up.

10.1159/000536064 article EN Respiration 2024-01-01

Abstract Chronic obstructive pulmonary disease (COPD) is a chronic and often progressive disorder with heterogeneous presentation frequent systemic manifestations. Several aspects like persistence in smoking habit, continuous exacerbations, alpha-1-antitrypsin deficiency inflammatory-immune response, are involved the pathophysiology progression of disease. However, role natural killer (NK) cells remains controversial. Otherwise, human cytomegalovirus (HCMV) infection has been reported to...

10.1186/s12931-020-1323-4 article EN cc-by Respiratory Research 2020-03-04

Abstract Background Supplemental oxygen delivered with standard therapy (SOT) improves exercise capacity in patients idiopathic pulmonary fibrosis (IPF). Although high-flow nasal cannula (HFNC) oxygenation other respiratory diseases, its impact on performance has never been evaluated IPF patients. We hypothesized that HFNC may improve subjects compared to SOT. Methods This was a prospective, crossover, pilot randomized trial both methods during constant submaximal cardiopulmonary test (CPET)...

10.1186/s12890-021-01727-9 article EN cc-by BMC Pulmonary Medicine 2021-11-08

Different clinical predictors of physical activity (PA) have been described in idiopathic pulmonary fibrosis (IPF), but studies are lacking evaluating the potential role muscle strength and anxiety depression symptoms PA limitation. Moreover, little is known about impact changes course disease. The aim present study was to investigate relationship between baseline a wide range variables IPF, assess its longitudinal at 12 months on progression free-survival.PA assessed by accelerometer...

10.1186/s12890-022-02134-4 article EN cc-by BMC Pulmonary Medicine 2022-09-09

More than 60% of patients with lung cancer are diagnosed at advanced stages. The introduction targeted therapies requires molecular diagnosis to guide treatment. aim this study was evaluate the feasibility performing mutational analysis brushing specimens obtained by radial-miniprobe endobronchial ultrasound (R-EBUS) plus fluoroscopy-guided bronchoscopy in peripheral pulmonary adenocarcinoma.Brushing were deposited on cytological slides and conserved Roswell Park Memorial Institute (RPMI)...

10.1002/cncy.22053 article EN Cancer Cytopathology 2018-10-01

Tumor recurrence is frequent and survival rates remain extremely low in lung adenocarcinoma (ADC). We hypothesize that carcinogenic factors will promote loco-regional modifications not only the future tumor, but throughout exposed lung. Objective: To analyze whether most prevalent mutations observed ADC can also be non-neoplastic tissue, as well short-term prognosis implications of this finding. Methods: Non-tumoral parenchyma specimens obtained during surgery from 47 patients with EGFR...

10.3390/jcm8040529 article EN Journal of Clinical Medicine 2019-04-17

Abstract Background Diaphragm fiber atrophy has been evidenced after short periods of mechanical ventilation (MV) and related to critical illness-associated diaphragm weakness. Atrophy is described as a decrease in cross-sectional area (CSA) human biopsy, but samples are still difficult obtain clinics. In recent years, ultrasound become useful tool intensive care evaluate anatomy. The present study aimed the ability expiratory thickness (Tdi) measured by predict atrophy, defined CSA obtained...

10.1186/s40560-022-00632-5 article EN cc-by Journal of Intensive Care 2022-08-19

Background: Hypercapnic encephalopathy is relatively frequent in severe exacerbations of COPD (ECOPDs), with its intensity usually being evaluated through clinical scales. Bispectral index (BIS) a new technique, based on the analysis electroencephalographic signal, which provides good approximation to level consciousness, having already been validated anesthesia. Objective: The objective study was evaluate utility BIS assessment hypercapnic ECOPD patients. Patients and methods: A total ten...

10.2147/copd.s167020 article EN cc-by-nc International Journal of COPD 2018-09-01

Lung cancer is a malignant tumor with high morbidity and mortality worldwide. At present, the main treatment methods for patients advanced non-small cell lung (NSCLC) include molecular targeted therapy immunotherapy. The efficacy rate of immune checkpoint inhibitor (ICI) monotherapy relatively low. Studies have confirmed that some combination therapies better anti-tumor higher response rates, such as PD-1/PD-L1 inhibitors combined chemotherapy or therapy. Poly (ADP-ribose) polymerase (PARP)...

10.21037/atm-22-3582 article EN Annals of Translational Medicine 2022-08-01
Coming Soon ...